JP2014516049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516049A5 JP2014516049A5 JP2014512115A JP2014512115A JP2014516049A5 JP 2014516049 A5 JP2014516049 A5 JP 2014516049A5 JP 2014512115 A JP2014512115 A JP 2014512115A JP 2014512115 A JP2014512115 A JP 2014512115A JP 2014516049 A5 JP2014516049 A5 JP 2014516049A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- cys
- lys
- substituted
- enhancing moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 13
- 230000002708 enhancing effect Effects 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 208000008279 Dumping Syndrome Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 208000032395 Post gastric surgery syndrome Diseases 0.000 claims 1
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489781P | 2011-05-25 | 2011-05-25 | |
| US61/489,781 | 2011-05-25 | ||
| PCT/US2012/039431 WO2012162542A1 (en) | 2011-05-25 | 2012-05-24 | Amylin peptides and derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014516049A JP2014516049A (ja) | 2014-07-07 |
| JP2014516049A5 true JP2014516049A5 (enExample) | 2015-07-09 |
Family
ID=47217749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512115A Withdrawn JP2014516049A (ja) | 2011-05-25 | 2012-05-24 | アミリンペプチドおよび誘導体ならびにそれらの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20140221287A1 (enExample) |
| EP (1) | EP2714067A1 (enExample) |
| JP (1) | JP2014516049A (enExample) |
| KR (1) | KR20140045433A (enExample) |
| CN (1) | CN103826655A (enExample) |
| BR (1) | BR112013030067A2 (enExample) |
| CA (1) | CA2837104A1 (enExample) |
| CL (1) | CL2013003377A1 (enExample) |
| CO (1) | CO6821894A2 (enExample) |
| EA (1) | EA201391763A1 (enExample) |
| IL (1) | IL229449A0 (enExample) |
| MX (1) | MX2013013802A (enExample) |
| PH (1) | PH12013502385A1 (enExample) |
| SG (1) | SG194998A1 (enExample) |
| TN (1) | TN2013000491A1 (enExample) |
| WO (1) | WO2012162542A1 (enExample) |
| ZA (1) | ZA201309679B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2068909T3 (pl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modyfikowane polipeptydy fgf-21 i ich zastosowanie |
| JP6728141B2 (ja) * | 2014-09-04 | 2020-07-22 | ノヴォ ノルディスク アー／エス | 新規のアミリン及びカルシトニン受容体アゴニスト |
| CN104327162A (zh) * | 2014-09-28 | 2015-02-04 | 苏州普罗达生物科技有限公司 | 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用 |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| WO2018144671A1 (en) * | 2017-02-01 | 2018-08-09 | The Research Foundation For The State University Of New York | Mutant islet amyloid polypeptides with improved solubility and methods for using the same |
| CA3097812A1 (en) * | 2018-04-25 | 2019-10-31 | Janssen Pharmaceutica Nv | Thioether cyclic peptide amylin receptor modulators |
| JP7652422B2 (ja) | 2018-11-02 | 2025-03-27 | ベイジン ブイディージェイバイオ カンパニー， リミテッド | 修飾されたｃｔｌａ４およびその使用方法 |
| EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| CN110467666A (zh) * | 2019-09-17 | 2019-11-19 | 湖北强耀生物科技有限公司 | 一种新型胰岛淀粉样多肽的合成方法 |
| TW202400632A (zh) | 2021-03-03 | 2024-01-01 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| WO2023086499A1 (en) | 2021-11-10 | 2023-05-19 | I2O Therapeutics, Inc. | Ionic liquid compositions |
| WO2023227133A1 (zh) | 2022-05-27 | 2023-11-30 | 杭州先为达生物科技股份有限公司 | 人胰淀素类似物、其衍生物及用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2233497A3 (en) * | 2004-02-11 | 2011-01-12 | Amylin Pharmaceuticals, Inc. | Amylin family peptides and methods for making and using them |
| EP1853627A2 (en) * | 2005-02-11 | 2007-11-14 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| WO2007104789A2 (en) * | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Amylin derivatives |
| EP2036539A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| US8946148B2 (en) * | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
-
2012
- 2012-05-24 JP JP2014512115A patent/JP2014516049A/ja not_active Withdrawn
- 2012-05-24 CN CN201280036795.0A patent/CN103826655A/zh active Pending
- 2012-05-24 SG SG2013084892A patent/SG194998A1/en unknown
- 2012-05-24 EP EP12789229.7A patent/EP2714067A1/en not_active Withdrawn
- 2012-05-24 BR BR112013030067A patent/BR112013030067A2/pt not_active IP Right Cessation
- 2012-05-24 PH PH1/2013/502385A patent/PH12013502385A1/en unknown
- 2012-05-24 CA CA2837104A patent/CA2837104A1/en not_active Abandoned
- 2012-05-24 US US14/119,574 patent/US20140221287A1/en not_active Abandoned
- 2012-05-24 MX MX2013013802A patent/MX2013013802A/es not_active Application Discontinuation
- 2012-05-24 KR KR1020137033991A patent/KR20140045433A/ko not_active Withdrawn
- 2012-05-24 EA EA201391763A patent/EA201391763A1/ru unknown
- 2012-05-24 WO PCT/US2012/039431 patent/WO2012162542A1/en not_active Ceased
-
2013
- 2013-11-14 IL IL229449A patent/IL229449A0/en unknown
- 2013-11-22 TN TNP2013000491A patent/TN2013000491A1/fr unknown
- 2013-11-25 CL CL2013003377A patent/CL2013003377A1/es unknown
- 2013-12-19 CO CO13296527A patent/CO6821894A2/es not_active Application Discontinuation
- 2013-12-20 ZA ZA2013/09679A patent/ZA201309679B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516049A5 (enExample) | ||
| JP6985345B2 (ja) | グルカゴン及びｇｌｐ−１共アゴニスト化合物 | |
| JP6903086B2 (ja) | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 | |
| JP6345216B2 (ja) | オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途 | |
| CN114901682B (zh) | 胰岛素衍生物 | |
| JP6549741B2 (ja) | ペグ化ｏｘｍ変異体 | |
| JP6121330B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| JP6412183B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| JP6363612B2 (ja) | オキシントモジュリンと免疫グロブリンのフラグメントとを含むタンパク質結合体の液状製剤 | |
| JP2012506402A5 (enExample) | ||
| US9879063B2 (en) | Engineered polypeptides having enhanced duration of action and reduced immunogenicity | |
| JP2014525901A5 (enExample) | ||
| JP2013518115A5 (enExample) | ||
| JP2011524420A5 (enExample) | ||
| WO2013004983A1 (en) | Novel compounds and their effects on feeding behaviour | |
| JP2017531613A5 (enExample) | ||
| JP2025525218A (ja) | インクレチンアナログおよびその使用 | |
| BR112017024684B1 (pt) | Compostos coagonistas de glucagon e glp-1, composição farmacêutica, uso, processo de produção e composto intermediário dos mesmos | |
| HK1211856A1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |